Home / Transcripts / Demant A/S (DEMANT) · February 5, 2025

Demant A/S (DEMANT) Earnings Call Transcript

February 5, 2025

Nasdaq Copenhagen DK Health Care Health Care Equipment and Supplies earnings 60 min

Earnings Call Speaker Segments

Peter Pudselykke executive
#1

Good afternoon, and welcome to the conference call we're holding after releasing our first integrated annual report for 2024 earlier today. Here on this call, things will proceed as usual: we intend to walk through the presentation, and after that we'll take Q&A. <<operator_script>> Joining us in the room today are the usual team and representatives. Present are Søren Nielsen, our President and CEO; René Schneider, our CFO; and also Gustav Høegh plus myself, Peter Pudselykke, from the IR team. That covers the practical elements, so over to you, Søren, for the presentation.

Søren Nielsen executive
#2

Thanks a lot, Peter, and hello everyone. Today's agenda covers the usual key events, financial takeaways, plus a bit more on sustainability advancements and a business area review. René will walk through the group financial review. I'll speak to the outlook, and after that we'll open it up for Q&A. Financial highlights for 2024: 4% reported growth, with 2% from organic growth and 2% from acquisitions, and overall revenue rose to DKK22.4 billion, gross profit improved 5%, EBIT declined DKK100 million, roughly speaking 2%, but cash flow from the group was very strong. On key events, momentum in HearingCare has been very good and carried through toward the end of the year, with a strong organic growth rate across a high number of markets and growth rates above the market, so super solid. Hearing aids growth came in below our original expectation, hit by a generally strong competitive environment, but more importantly by the brand strategy choice in the U.S. that cost us significant market share back in the second quarter. Diagnostic growth was affected by soft markets, yet even in deadlight, or in deadlight, we estimate our organic growth rate was above the market growth rate. We completed the divestment of the CI business in summer.

Søren Nielsen executive
#3

And during the year, we also made the decision to divest the communication business — two very important steps toward becoming a more focused hearing healthcare company — and then, in the fall, we carried out restructuring in communication EPOS. That means in Q4, as expected, we saw a positive profit from both the communication business and the bone-anchored hearing system business. So together, the two posted a positive result, which was also in line with expectations. Key financial takeaways for the second half: organic growth in the second half came in at 2%, and likewise for the year, despite a strong comparison base. And again, despite the loss of market share in the managed care channel in the U.S. and in line with our most recent expectations. Despite a continued good ASP in hearing aids, gross profit declined by 0.4 percentage points. This relates to exchange rate and more and more over hearing aids — René will comment more on that. We see it as more of a temporary nature. And yes, René will comment more on that. We did manage, as expected, to significantly lower the growth rate of OpEx in the second half down to 2%, significantly down from the first half; acquisitions added an additional 4 percentage points.

Søren Nielsen executive
#4

EBIT before special items came in at DKK2.236 billion, essentially level with the second half of ‘23, though better than the first half. And yes, exchange rates had a negative effect, and naturally, we also saw reduced operating leverage because the top line was softer. Cash flow was very strong. Operating cash flow reached DKK2.6 billion, and free cash flow came in just above DKK2.3 billion. On the revised outlook, which we’ll discuss further, it points to 3% to 7% organic revenue growth, EBIT before special items of DKK4.5 billion to DKK4.9 billion, and buybacks exceeding DKK1.5 billion. We published our first integrated report covering both financials and sustainability. Demant’s number one purpose is helping more people hear better, and one element of this sustainability reporting is the count of improved lives, which stands close to DKK11 million. As you’d say, this is a cumulative figure over time, built on certain assumptions about expected product lifetimes in the field, etcetera. We also began reporting the number of hearing tests carried out in our own hearing clinics, and we reached 1.5 billion of those. Another area covered in the report is respect for the planet, including the reduction in Scope 1 and 2 emissions, and you can see a nice positive downward trend there, plus, under caring for people, growing gender diversity within our leadership team.

Søren Nielsen executive
#5

This is also a positive, steady development. We beat our target slightly ahead of schedule, and as a result, new ones, and then acting with integrity — that's a new metric in which we examine how many people are, so to speak, exposed above average to elements of a solid code of conduct and thus receive more focused training — and we've reached 76% of those people thus far, and of course we will soon arrive at 100. Business area review, the hearing aid market first in '24: the fourth quarter worldwide grew, by our estimate, 5%, which matches precisely the annual expectations, lifting the annual growth rate to 4% from after the third quarter, more toward the tree. Europe has growth below average, mainly because of slightly negative growth in the NHS, while Germany delivered nice growth and France also grew positively, making the full year end slightly positive, the first time since the reform in '21. The U.S. keeps up good, strong momentum on the commercial side. Those should be mentioned: an easier comparison base, VA stays flat, and also strong development in Canada. Emerging markets, rest of the world, generally performed well in the second half and best in the fourth quarter, again, all in all, adding up to the 5%.

Søren Nielsen executive
#6

We continue to estimate that, given channel mix and country mix, et cetera, ASP development in the market has been slightly positive this year. And naturally, our own results should be viewed against that backdrop. In hearing aids during the fourth quarter, organic growth came in at minus 1% to external customers, hit by a tough comparison base and, naturally, by share loss in managed care and, a, clearly a fiercely competitive environment. That said, I would note that sequentially we have held our value market share, and we keep seeing solid, strong ASP development in the second half — specifically minus 1% in units with ASP at plus 5%, which naturally reflects both channel and product mix. Good performance across many medium-sized markets, yet negative growth in France, Germany, UK, essentially all attributable to the larger change. U.S. positive in Q4, also driven by the larger change, and slightly negative in Canada, though purely because of a very high comp in Q4 last year — nothing when viewed on a run-rate basis. The Canadian business continues to perform well. Strong growth in Asia, with positive growth in China despite weak markets, and solid results as well in Australia and South America.

Søren Nielsen executive
#7

Also, as we keep broadening the product lineup, we're still gaining from a highly power-efficient core platform running a completely integrated DNN, which helps bring power usage down. It runs continuously and has no meaningful effect on the battery size we're able to use, so we've also managed to get it working on the industry's smallest battery — the so-called 10A battery — which is what goes into the very small CIC and IIC styles, and that's what we're now launching with the full advantage of the DNN operating all day long, so a really powerful concept and a very high-performing set of products coming out here in February. Beyond that, we're also widening our lower-priced range with mini BTEs, mini rides, India products, and for the first time with DNN performance or technology elements in really strong concepts that should likewise fuel growth in the more lower-priced segments in the markets where that matters. Hearing care in the fourth quarter: very strong performance, continuing strong and solid momentum across many mid-sized markets and in North America, plus still a good contribution from acquisitions during the quarter, mainly in Denmark, Germany and Italy, consistent with our strategy of building critical mass in chosen markets and expanding in Germany.

Søren Nielsen executive
#8

Unit volume was the main source of growth. During the period, the basics came from having additional stores and a larger network, plus a modest ASP benefit arising from both product and geographic mix. We saw positive growth in France — slightly positive growth in France — along with strong growth in the UK, Poland and Germany; good growth in the U.S. as well, where despite exiting managed care programs we succeeded by generating traffic on our own; strong growth in Canada; negative growth in China, where weak market conditions continue to hurt us; and a strong performance in Australia too. Diagnostics kept facing headwinds from soft markets in the diagnostic business, and on top of that, limited access to the government market — a public market in China — because of insufficient products meeting the made in China requirement, with nice growth in service and consumables. And outside China, the main negative growth would be in France and Germany, largely tied to comps, but also in the U.S., where we saw some orders postponed from '24 into '25. With that, I'll hand it over to you, René.

René Schneider executive
#9

Thanks, Søren. Now, turning to revenue for the second half of the year. Organic growth came in at 2%, mainly driven by hearing care, while hearing aids and diagnostics posted negative growth, partly because of the strong comparative figures. Acquisitions added 3 percentage points, in both hearing aids and hearing care, and we saw a growth effect of minus 1 percentage point from FX. On gross profit, it rose by 3% to roughly DKK8.6 billion. Gross margin fell by 0.4 percentage point compared with the second half of last year, even though ASP in hearing aids remained strong. That was mainly due to an exchange rate effect — a negative exchange rate effect — as well as a high share of rechargeable units, but also, particularly in Q4, gross margin took a hit from increased sales to a certain large account. On OpEx in the second half of the year, we saw very low organic growth of 2%, just as expected, and that reflects the strong focus we've had since midyear on bringing organic growth of OpEx down to be balanced with organic growth of sales, and we've managed that. Acquisitions contributed 4% to growth, in line with our acquisition strategy, and we saw no FX effect.

René Schneider executive
#10

Turning to group operating profit, we posted DKK2.36 million in the second half, essentially a flat development versus last year, which means an EBIT margin of DKK20.6 million — a contraction of 0.9 percentage point. That EBIT margin took a negative hit in the second half from the exchange rates I mentioned earlier and also from lower operating leverage, especially within hearing aids on the gross margin side. We additionally saw year-over-year dilution stemming from M&A activities, which tend to be short-term in nature as well. On the cash flow statement for the second half, again very solid — continued very solid cash flow generation. Cash flow from operations rose 2% versus last year, driven by a significant improvement in net working capital. CapEx came in at approximately 3% of group revenue, slightly under our normal expectations for the fall, so that contributed too. And net cash to acquisitions and divestments was minus DKK471 million in H2, entirely tied to hearing care and slightly above our normal guidance, though in line with our most recent expectations. Share buyback in the second half came to just above DKK1.1 billion, taking it to DKK2.3 billion for the full year. Turning to key financials for the full year, we finished with 2% organic growth against a very strong comparative base.

René Schneider executive
#11

And just to jog your memory, organic growth in ‘23 came in at 14%, which means 16% across 2 years. Gross margin was up 0.6 percentage points, helped by a better-than-expected gross margin in H1 stemming from the business mix effect and strong development in the ASP in hearing aids coming from, in particular, the intent launch we carried out in the first quarter. Organic OpEx growth for the year was 4%, significantly lower in H2 as we have just gone through. So we achieved a better balance between revenue growth and OpEx growth. Acquisitions contributed 4 percentage points to the overall growth of 8%. That gave us EBIT for the full year of DKK4.4 billion and an EBIT margin of 19.6%, slightly below last year, reflecting lower operating leverage, particularly in hearing aids, plus a negative year-over-year effect from exchange rates, particularly in H2. We saw strong cash flow from operations for the full year of just above DKK4 billion and roughly DKK3.5 million in free cash flow for the full year, along with share buybacks, as I mentioned earlier. Finally, on balance sheet items, the balance sheet rose by 6%, primarily driven by acquisitions made throughout the year, and that produced an increase particularly in goodwill, while net working capital declined by 9%, primarily though because of a reclassification of communication to assets held for sale.

René Schneider executive
#12

Compared with midyear, though, net working capital came down 7%, thanks to a strong emphasis on cash flow, which brought about a reduction in inventory and trade receivables. At the full year, or the end of the year, we finish with net interest-bearing debt of DKK13.5 billion and a gearing multiple of DKK2.3 billion, which sits comfortably within what we expect over the medium to long term. So with that, let's move to outlook.

Søren Nielsen executive
#13

Yes. Thank you, René. And just quickly regarding the market — the assumptions we made prior to setting the outlook are a normal 4% to 6% growth in units and a flattish ASP for the year, so also in value. We expect — and this is after looking more into the numbers, but also what we sense here in the beginning we have come to the conclusion that we now expect the French market to grow high single-digits in 2025. For the group, the outlook, it is important to remind yourself of the comps in Q1 being particularly high due to the managed care as well as a strong product introduction last year, therefore, likely that the Q1 organic growth rate will come in below the full year outlook. This is totally to be expected when that, at some stage come out. We expect the cash allocation to bolt-on acquisitions to be higher than normal due to a continued good pipeline and good opportunities. And we have not included any significant financial impact from potential tariffs related to U.S. in our outlook simply too difficult to predict. So, it makes no sense to sit and guess. Discontinued operation, we continue to have the communication and bone-anchored as discontinued business.

Søren Nielsen executive
#14

For those businesses combined, we anticipate net profit after tax landing somewhere between 0 and 50 million plus. That figure relates purely to operating profit and leaves out any financial effect tied to the planned divestment of the two businesses. So to sum up overall, organic growth should come in at 3% to 7%, with two of those points stemming from market uncertainty, EBIT ranging from DKK4.5 million to DKK4.9 billion as mentioned, and a share buyback exceeding DKK1.5 billion. Acquisitive growth — purely for modeling purposes here — is projected at 2%, based on revenue from acquisitions already closed as of today. With currencies at today's levels, we anticipate a 1% addition on the top line, hedging impact included. The effective tax rate should be roughly 23% and, again, profit from discontinued operations in the area of 0 to 50 million, gearing ratio, no changes versus what René also just referenced, our medium- to long-term target of 2x to 2.5x, yes, by the full — by year-end. Yes, over to Q&A.

Operator operator
#15

Our first question this session is from Richard Felton at GS. Richard, the floor is yours.

Richard Felton analyst
#16

Thanks. Good afternoon. I have just 2 questions, please. The first concerns the U.S. hearing aid business, and more specifically, the trends you are seeing in the independent channel in that market. So, part one: how did your market share evolve over the course of the year in that channel? And then, second, as you think about the shift in your U.S. brand strategy, managed care has obviously been a headwind, but are you beginning to see any of the benefits you anticipated from that strategic shift starting to materialize? That is question one. Question two concerns the Diagnostics business. I appreciate that the overall market was soft in 2024, but can you give any color on what was actually driving that market weakness, and as we look out into 2025, how should we think about those headwinds? Thank you.

Søren Nielsen executive
#17

Yes, thank you so much for that question. We don’t go into a lot of specifics, but let’s look at the big picture regarding the independent channel. We had a very strong launch during the first half, which naturally gives your market share a boost, since you tend to push a lot of products into the market. So half year over half year, we saw some decline in market share. But during the second half, we’ve seen stable development — of course, when others then introduce products, you get a bit of a reverse effect where in a given month your market share can go down, but then come back up. And all in all, we have at least maintained our share during the second half in the independent channel, and whether or not our managed care strategy is part of building that defense against other introductions. So now it is, of course, a little bit difficult to say. You can only look at the totality, but yes, I think there are definitely good examples of people that have benefited from the strategy. But of course, as I said earlier, it can never compensate for where the change brand strategy ended, which was that we basically lost a number of important contracts, and we are still working to make sure we find a way back into a higher share in the managed care channel.

Søren Nielsen executive
#18

We didn’t plan to end up where we did, so significant work remains in that area. Turning to diagnostics, once again China accounts for it through lack of access. So of course you could argue that isn’t truly a market weakness but rather access problems. On the market side, we’ve observed Europe being somewhat soft, yet particularly in the U.S., we’ve seen investments shifted from ‘24 into ‘25; across all markets we continue to see a solid pipeline, and so the basis for the ‘25 assumptions is normal market development of roughly 5%.

Richard Felton analyst
#19

Thanks a lot, Søren.

Operator operator
#20

We’ll now take the next question from Julian Ouaddour at Bank of America. Go ahead.

Julian Ouaddour analyst
#21

Thanks a lot for taking my questions. I've got two as well. First, Søren, we're seeing an increasing number of competitors push into DNN, an area you occupied some years back. So do you believe DNN is turning into a standard feature for hearing aids, and I'd like to know how you keep differentiating yourself against the peers? And also, could you explore a real-time AI technology along the lines of what Sonova has, purely to further set yourself apart in DNN versus the new entrants? That's the first question. The second one, in your 2025 guidance, you assumed the French market would grow in the high single-digit territory, thanks to the reform anniversary. Could you detail your assumption a bit, especially regarding the percentage of customers who will replace their Class 1 devices, how many might potentially trade up to Class 2 as well, and any indication on timing too? Do you expect material benefits already in Q2, or is it somewhat more back-end loaded? Thank you.

Søren Nielsen executive
#22

Thanks a lot for those questions. Regarding the technology, I wouldn’t describe DNN as a feature. The feature is the application of it—noise management, speech enhancement, whatever purpose you put it to—that’s what a technology is. I have no doubt, and I’ve been saying this for some time, that using AI, deep neural networks—which to me are two names for more or less the same thing—is the direction hearing aid design is heading. Signal processing is quicker there. It handles more dynamics. It responds faster when adjustments are needed. The basic way of handling speech and noise can still differ greatly. How do you make use of the multiple microphones on the device? Do you still employ them to focus on a speaker you want to hear, or do you listen in every direction? That ties back somewhat to how we’ve approached things. We’ve made it a priority to use it for strengthening the contrast between speech and noise. We still firmly think people want ambience and an awareness of the non-speech sound environment too. What matters is the philosophy of being able to hear multiple speakers all around.

Søren Nielsen executive
#23

We have a setup that places no constraints, as we now demonstrate with our new introduction regarding device size and the classical batteries to be employed. Should you begin adding extra chips, boosters, or DNNs on a separate basis, you'll encounter some overhang—at minimum up to your power consumption thus far—and that will impose certain limits either on how much you can utilize it, or on how aggressive you can be, or on what battery size you have. I still consider us to be in a very strong competitive position. The patient benefit—the patient performance is extremely robust. And ultimately, patients don't truly grasp how you've applied AI or how it actually functions. They will invariably focus on the outcome, and so we will train our geologies. Thus I believe we are well positioned. And regarding your second question on the French, it's too early to state precisely the 8—or rather not the 8, the high single-digit is, naturally, in units. We do anticipate some ASP decline since we assume we'll see additional Class 1 devices arriving. So how that unfolds is somewhat uncertain. The pace at which we'll observe it—naturally, there are those who act immediately.

Søren Nielsen executive
#24

Some folks go with one, year 5, year 6. We do anticipate a decent level of uptake in the first half, since that's also where a lot of people came in initially, and there's a 48-month cycle rather than a particular year. So we should expect that, and we're also seeing very early signs of good uptake in traffic from existing users into the stores. We're obviously in close contact because they're in our database, etcetera, so overall, a good indication for the year. And I'd also say that compared with our hesitancy in the fall about being very explicit, this is a — I'd call it a positive indication for what we've seen so far.

Julian Ouaddour analyst
#25

Thanks a lot, Søren. I’ve got one quick follow-up to Richard’s question regarding market share. On the slide, you noted that the U.S. commercial market rose 7%. Managed care was probably a headwind of a couple of percentage points, but hearing aids declined this quarter. You also said you’re holding market share in U.S. independent. So I just want to understand the momentum exactly here, and how it’s possible to keep market share stable—and maybe any comment on market share in Europe as well, like is that where you saw some decline? Any color would be super helpful. Thank you.

Søren Nielsen executive
#26

Yeah. I mean, the channel mix and development differ considerably between the U.S. and Europe. As I mentioned, we’ve been losing sales to several larger accounts over in Europe, while our share with independents in the U.S. has held steady. Again, it swings quite a bit from month to month, since this is a sell-in metric and there’s been a lot of introduction activity. So it’s naturally an estimate in value terms as well, and once more, our product mix remains very strong and solid. That’s the basis for us saying we think we’ve held share among U.S. independents, excluding the Managed Care segment, during the second half.

Julian Ouaddour analyst
#27

That’s great. Thanks a lot.

Operator operator
#28

David Adlington from JPMorgan has our next question. Go ahead, please.

David Adlington analyst
#29

Three questions. Perhaps starting with managed care: I was just wondering whether you could say how big an organic growth headwind managed care was in 2024, and what your 2025 guidance assumes about getting back into managed care later in the year?

Søren Nielsen executive
#30

David, that was a pretty rough line, but I believe we caught the question. René has something to add.

René Schneider executive
#31

Yes. So — you could describe the managed care headwind we're up against in the first quarter of 25% as adding roughly 3 percentage points of growth on hearing aids, which would work out to about 1% at the group level, around those numbers.

David Adlington analyst
#32

Does your guidance factor in a return to managed care at some point later this year?

Søren Nielsen executive
#33

I'd say a managed care business that's expanding is included in the guidance, and the reason for the uncertainty about organic growth — about what level it will reach — is that it's far too soon to say anything about timing, or whether it happens, or how much, or with whom, and so forth.

David Adlington analyst
#34

So for France, with high-single digit growth across the full year, does that imply you're looking for double-digit growth from Q2 through Q4, since I'd expect Q1 to show fairly little growth?

Søren Nielsen executive
#35

No, I think it could be spread fairly evenly across the year. Naturally, we aim to establish a solid pipeline right from the start. I realize the invoices are somewhat behind, though not by enough that you'd notice a very meaningful gap in uptake. But then again, whether it comes early or late, I believe it's too soon to say. What we're assuming is a fairly even spread over the year. Going into more detail than the assumed 8% for the full year is still premature. Sorry, 8%—sorry, the assumed mid-single digits, apologies.

David Adlington analyst
#36

And the last question from me. I was just hoping for any update on that new contract with AI.

Søren Nielsen executive
#37

Nope.

Operator operator
#38

Martin Brenoe from Nordea has our next question — go right ahead.

Martin Brenoe analyst
#39

Hello. Søren and René, thank you for fielding my questions. I have just two, if I may. The first concerns the guidance. My understanding is that your guidance implies growth in the high-single digits during H2 in order to land at the top end of your range. Could you help me, as an outsider, understand how you plan to get there? Specifically, what does that require in terms of market growth, ASP, market share, and perhaps managed care — maybe walk through some of the building blocks toward that. That is my first question. My second question: I imagine it is reasonable to assume that EBIT in absolute terms, and perhaps also where the margin is concerned, will be fairly back-end loaded in 2025, with growth lower in H1 and then picking up in H2. So I am trying to work out just how much of the profitability will be skewed toward H2. Should we expect that you are at present, for instance, positioning yourselves for faster growth in H2 — for example, from France — and that you are right now putting money into marketing and getting ready for that opportunity in Q1 or Q2, with an expectation of a return in H2 from that?

Martin Brenoe analyst
#40

Would you say that's a reasonable way to think about how EBIT will trend?

Søren Nielsen executive
#41

Actually, Martin, I'd flip that around a bit. The comps, I'd argue, are the main reason behind that growth rate, which is why it looks so uneven through the year. On the EBIT side, I'd say it's just naturally spread out in a growth company. Given how we've always done things, you've consistently seen a certain balance between the first half and the second half. That's simply the way it is. And this year, looking back, I'd say we aren't planning for anything out of the ordinary.

René Schneider executive
#42

Looking back at 2024, the seasonality on operating profit was somewhat unusual, while for 2025 we don’t view it as showing any notable seasonal pattern. Typically, EBIT in the second half of the year is simply bigger than in the first half. That’s our view.

Martin Brenoe analyst
#43

All right, thanks. And then regarding how you get to that high-single digit growth, meaning above the 7%, what gives you confidence that you can actually deliver that?

Søren Nielsen executive
#44

Naturally, that’s a favorable move in the market. It’s solid growth momentum across the year, and it can come from plenty of channels. But naturally, we do have plans for the year aimed at taking share. So at that level, with a strong market, it could be France performing at the higher end of the high-single digit, etcetera. So it is — there isn’t just one factor.

René Schneider executive
#45

I've already covered the opportunity that still exists in managed care, and that opportunity isn't present.

Søren Nielsen executive
#46

Thus, share gains are concentrated at the high end. And naturally, the question is how much, and at the very top, there’s also a market in the upper portion of that 4% to 6% range.

Martin Brenoe analyst
#47

All right, that’s quite clear. Thanks very much for taking my questions.

Operator operator
#48

Maja Pataki from Kepler has the next question. Please go ahead.

Maja Pataki analyst
#49

Hello, and good afternoon—thank you for taking my questions. Søren, I have a quick one. This week we saw a product announcement, and it is also based on DNN, but there has likewise been plenty of working words surrounding AI, and I know you have worked with DNN over a long period. Yet only now have you ramped up the wording around AI. Given that the intent was launched 12 months ago, do you feel you were rather conservative, or were you different in how you were promoting the product in the market—holding back with the AI wording and buzzwords? Do you think there is a disadvantage for you now in the next six months, until everyone has tried the products and made up its mind, so 2025 could be a bit more challenging when it comes to finding the right product—or do you think it really doesn’t matter? So, buzzwords and audiologists can see through that. That’s question number one. Question number two, can you provide us an update on communication—what is the timeline there, or what are the next steps that we should be expecting for you to take in communications? And lastly, René, just to double check, I believe you said that the headwind on growth for hearing wholesale would be 3% from managed care in Q1.

Maja Pataki analyst
#50

So that's likely the figure we need to consider as well for the final three quarters of 2024?

René Schneider executive
#51

Yeah, absolutely. Well, you could put it this way: we do face that headwind in Q1 of ’24, but the situation is much the same across the final three quarters of ’24.

Maja Pataki analyst
#52

That’s great to hear. Thanks a lot.

Søren Nielsen executive
#53

Then the other point, and this will be quick, on AI: I'd describe DNN as the actual technology, while AI is more of a buzzword. Actually, I was in the U.S. not long ago and put the question to several of our audiologists. Whether you call it one thing or the other, they don't really mind. And it isn't the term they use with the end user. So — their argument centers on what it does and how you're able to hear. We've also added somewhat more AI than we had at the start, but at its core the technology is a trained network. That, I think, is what lets audiologists grasp it, and they have some sense of what it does. I also notice that our competitors, once you get past the front page, are explaining the same thing. So there's a bit of buzzword quality to AI — the general audience understands it better, but for some it also carries a negative connotation of automation, something entirely different from what actually goes on inside the product. So, coming back to your question and the question underneath it: no, I don't believe we'll see six months of, I believe <<inaudible>>, of course, the new products being launched, whether by us or by someone else, will get tried out.

Søren Nielsen executive
#54

That's something we're accustomed to. And I believe we're in a good position to communicate about intent, as well as additional new products and, more broadly, a robust portfolio that brings substantial benefit to end users. Regarding communication, the process is continuing. We'll share more once we have more information.

Maja Pataki analyst
#55

All right, that's great. Thanks very much.

Operator operator
#56

Our next question is from Martin Parkhøi at SEB. Go ahead, please.

Martin Parkhøi unknown
#57

Yes. Thanks a lot, and good afternoon. Martin Parkhøi here from SEB. First, regarding the new AI-powered offering in a year or 2 years, could you tell me, Søren — as I understand it, it's only one version. So what's the major obstacle for you to actually do an AI <<inaudible>>, and do you really see this as an opportunity — a commercial opportunity — given that it isn't every chart of the version? And then a second question, maybe for René or Søren, whichever. We saw in the second half that, of course, the impact was smaller or perhaps zero in the fourth quarter. How should we view your sales developing into 2025? Do you expect to compete harder on these low prices, and then we'll see a smaller ASP impact or perhaps not even any? Of course, I know France also comes into the picture. And sorry if you've already had the question, but I was also…

Søren Nielsen executive
#58

Hi Martin. Yeah, I would. Coming back to IIC, CIC — for these extremely small products, re-chargeability, the approach we take here is fundamentally not an option. Building a custom, completely invisible <<inaudible>> device demands too much additional electronics. So that stems from the ambition of getting to IIC. The rechargeable element in custom, in my impression, or in what we do, still carries a significant sizing overhead. And that's a limited number of markets and, as we say, a limited total potential. So I'd say that falls under the bigger prioritization where cosmetics, design, where it's right in your product — we focus on the most discrete devices and so far, no viable solution on rechargeable. The ASP question hasn't come up, so all good. Into 2025, everything else equal, we'd expect stronger unit growth. We've basically had flat to slight negative last year, and the ambition is to grow in units. Not to give up any of a good strong position in premium in the good channels, but a more diverse channel mix and also, in some geographies, a slightly different product mix by selling more products at a lower price — not instead of but in addition to.

Søren Nielsen executive
#59

So as a result, a logical possible effect on ASP would lean downward rather than upward, alongside more robust unit growth. Yet once more, it hinges on how the market evolves and which markets expand the fastest—you could rapidly find regions, channels and so forth that actually deliver on both units and ASP. So as you know, it's extremely sensitive to a lot of parameters, but the overall direction and trend would be heavier on units and lighter on ASP.

Martin Parkhøi unknown
#60

I appreciate that.

Operator operator
#61

Our following question is from Andjela Bozinovic at BNP. You have the floor.

Andjela Bozinovic analyst
#62

Hello, and good afternoon. Andjela here, calling in from BNP. I have two questions, if I may. First, regarding the product: I gather that the new AI-enabled form factors introduced during the year, built on the Oticon Intent platform — are you able to share some data from the logical intense portfolio? And which form factors did you manage to launch? Beyond that, do you believe any additional platform launches will be necessary in 2025? Second, turning to Costco: what is your view on how competition will play out there in 2025, given that three months have now passed since your competitor came back? I am simply curious to hear whether you are noticing any shifts in market share across those stores. Thank you.

Søren Nielsen executive
#63

Thank you very much. Oticon Intent is a rechargeable mini-rite with a lot of different speakers that enables it to be basically from a mild hearing loss to a more severe hearing loss, so really, a wider application. Mini-rites <<inaudible>> is the most popular in the market for the majority of users. And in this price category rechargeability, I would say, is the standard, so a flexible solution, super good. And the addition we now do is the smallest in-ear products, which is for the premium product, the second most important category because if you don't go for a right, you typically want something even more discrete, not sitting behind the ear, but sitting in the ear. And again, we have managed to design it without any significant compromises or without any compromises just smaller, and therefore, a really strong concept. We think our Intent platform stands well, as I said before, against the competition. It has slightly different prioritization, but it has a number of unique benefits, again, the ability to listen to speakers for multiple directions at the same time even in a quite loud noise. It's low power consumption leading to unique small products like here and then that it's basically enabled all the time because of the low power consumption.

Søren Nielsen executive
#64

We don't need to sit around and limit it to particular scenarios. And when that restriction isn't necessary, you sidestep some of those lengthy transitions in and out that other players would face whenever the system kicks in and then kicks out again. So we believe we're positioned well. Regarding Costco, we hold a good, solid position there. We absolutely intend to keep that position or, if at all possible, grow it. Yes, it's a competitive environment as well, and I'm certain our competitors will attempt to — will bring out new products, and so on, and push activities; we intend to do the same.

Andjela Bozinovic analyst
#65

And just a quick follow-up regarding the products — so the Oticon Intend portfolio is now complete, meaning nothing further needs to be launched within the Oticon Intend platform. And I understand you won't give any color on the new platform, but a new platform does need to launch in 2025, given that these form factors have now been launched.

Søren Nielsen executive
#66

We haven't come out with form factors platform yet. The reason it's now tangible <<inaudible>>, we might not use the name Intent, but that underlying platform is going to be used across many additional styles down the road. There are quite a few form factors for which we still don't provide a complete solution. So the platform is nowhere near exhausted, and additional offerings will arrive and follow. And once again, the strength of the platform, I consider quite high even in today's competitive environment.

Andjela Bozinovic analyst
#67

Much appreciated.

Operator operator
#68

Niels Granholm-Leth from Carnegie is up next with a question. Go right ahead.

Niels Granholm-Leth analyst
#69

Thanks. I have a couple of questions. In the half-year report, you flagged lower activity involving a handful of bigger changes as a negative. How do you expect that measure to develop in 2025? And second, could you update us on what you anticipate for net financial items in 2025? Thank you.

Søren Nielsen executive
#70

Yeah, I'd say part of what I mentioned earlier about growing units reflects a focus and attention on lost market share in some of those channels. And so yes, I'd say that's part of the ambition for ’25. Not everything is done yet, but that is to grow sales to some of these or alternative channels that could otherwise compensate. I think you, René, on the net financials.

René Schneider executive
#71

A bit above that—so a touch worse than what we saw for ‘24—and that comes from effects that offset each other: somewhat more debt, yet on term loans, an interest rate that's somewhat lower.

Niels Granholm-Leth analyst
#72

So, just to get this straight, you're anticipating net financial costs that are slightly higher?

René Schneider executive
#73

Yes.

Niels Granholm-Leth analyst
#74

Thanks.

Operator operator
#75

Our following question is from Robert Davies at Morgan Stanley. Please proceed.

Robert Davies analyst
#76

I appreciate the opportunity to ask a few things—most topics have already been addressed. There were just a couple, and one concerned what we expect from the VA channel. Clearly, that channel has been fairly soft throughout 2024, with conflicting signals regarding expectations and growth, plus audiologist shortages and various other factors behind that weakness. I'd be interested in your perspective as we move into the year—what you're observing in hearing and how you think that particular market will develop? The second thing relates to your remarks about roughly flat ASP trends. Looking back over at least the past 2 years to 3 years, your pricing trends have in fact been considerably stronger than what historically would have been seen—that low-single digit deflation figure has actually turned positive. I was simply wondering why you're guiding toward more of that roughly flattish ASP outlook. That was the second item. And the third one, I suppose, is the obvious topic of tariffs. Could you remind us of your production versus sales mix—where across your business is that mismatch most acute?

Robert Davies analyst
#77

Thanks.

Søren Nielsen executive
#78

Yes. Thank you very much for the questions. We don’t have any particularly strong insight into VA, so it falls within the 4% to 6% guidance. There’s no doubt that the weak development in VA is a significant factor in pulling things down toward — toward the lower end of the 4% to 6%; could it happen again in ‘25, yes. Can it normalize, yes, I have no specific insight into that. And again, things can change over a year. On the flattish ASP, I still think that if you factor in channel mix development globally as well as geography, that’s part of the basis for it. Otherwise, you are right, we have raised prices due to inflation and also because of more advanced technology, most importantly, re-chargeability. So, our comment is that this — so far, these seem to have offset one another, giving a flattish ASP for the market. We have been in that market, improved our product mix and channel mix and therefore, seen clear growth higher than the market quite consistently over a period now. Of course, part of what I said earlier about just trying to sell into some of the channels where we don’t sell as much and have less share.

Søren Nielsen executive
#79

That’s not meant as a replacement — it comes on top of what we’re already doing, since naturally we’d want a solid share spanning both channels and geographies. So that’s included in how we’re planning for the year: seeking out opportunities over a wider area.

Robert Davies analyst
#80

Appreciate it. And regarding the tariff?

Søren Nielsen executive
#81

Yes. As for the tariff, we aren’t commenting. It’s extremely hard to predict and unclear — what, when, whether, and how — though I can tell you that all of our main production takes place in Poland and Europe. Along with that, we have some in Denmark too. And that’s the foundation; the best of what we have around the world in many, many countries is typically operations of different sizes to support building in-ear instruments like the one we just launched, performing service on the hearing aids, building ear molds, and so on. We do some of that in the U.S., and we do part of it outside the U.S.

Robert Davies analyst
#82

Got it. Thanks a lot.

Operator operator
#83

Our following question is from Carsten Lønborg Madsen at Danske Bank. Your line is open.

Carsten Lønborg-Madsen analyst
#84

Yes. Thanks a lot. And Søren, could you expand a bit on that top end of your EBIT guidance, the DKK4.9 billion figure? Reaching it would essentially mean EBIT growth of 11%, while organic growth is guided at up to 7%. And bear in mind too that you're saying growth in 2025 will come more from volume than from ASP, which I'd take to have a negative effect on gross margin — or at least not a positive one. So how would you potentially deliver that 11% EBIT growth? Is it partly about acquisitions, could currencies play a role, or will you generally be restraining OpEx?

Søren Nielsen executive
#85

We'll <<inaudible>> — it's just that you've witnessed the opposite effect this year, with scale benefits throughout the business, since a number of things are essentially fixed in cost, and so there's a scalability effect in that, I'd say. I don't know whether you have anything to add to that.

René Schneider executive
#86

Yes. So we're at 7%. Now, how do you actually reach that 7%? Fundamentally, it comes from taking market share in a market that's healthy and growing well. That's the scenario. And that translates meaningfully into operating profit, because there's scalability in operations too, and also despite a more normal unit ASP distribution, since it isn't selling incremental units that are, let's say, lower-priced rather than high-priced. On top of that, it would drive growth. So when you have this, you can point to more marginal contribution from low-priced hearing aids. It also isn't diluting the gross margin. So that's the effect you get. You have fundamentally one factory, right, and that's what distributes units. So growing through, you could say, more low-priced channels can also be very meaningful if it comes in addition to what we already do on the higher-price side.

Søren Nielsen executive
#87

And usually it doesn’t add any extra OpEx, so that’s really the core of the scale effect.

Carsten Lønborg-Madsen analyst
#88

All right. Then there’s one further question about your internal sales into hearing care: this quarter you’re growing them 18%, 18% last quarter, and 12% the quarter before. Meanwhile, retail sellout is 7, 7 and 5. I realize there are some phasing effects and so on, but can you explain what’s behind that fairly large gap between what you’re selling in and what has been sold out of the stores for quite a long time, I’d say.

René Schneider executive
#89

Yes. So that figure is going to be larger no matter what, correct. And the reason is that you’ve got organic growth on the hearing care side. Then there’s acquisition growth on the hearing aid side. And then, when we buy businesses, there’s the increased share of wallet, so what was typically a third-party product gets replaced by the Demant product. So we’ll sell additional product from the hearing aid side into our own clinics. So you’d always have to add not only organic and acquired, but increased share of wallet as well. So that’s how the math works, and the principle we follow is that the — you could say the arm’s length price between wholesale and retail in this calculation stays unchanged over time. So basically, apart from geography mix, it’s a unit measure.

Carsten Lønborg-Madsen analyst
#90

Yes. And I’ve got a quick question: René, you mentioned the opportunity that’s still left in managed care — should we read that as you’re making headway in your talks with the companies here, or is it more of the same as they were after Q3?

René Schneider executive
#91

No, it’s really the straightforward rebound from what we lost significantly in ‘24. So logically, there’s simply more upside to capture than further downside to give up, right, so that’s the situation.

Carsten Lønborg-Madsen analyst
#92

That’s great. Thanks very much.

Operator operator
#93

That brings our question-and-answer session to an end. Management, I'd like to hand the conference back to you for any closing remarks.

Peter Pudselykke executive
#94

Thanks, operator. I realize a few folks are still waiting in the queue, but please don't hesitate to contact us straight after this call, and we'll make every effort to assist you from there. Many thanks for being with us, and we're very much looking forward to meeting up with you during the roadshow over the next few weeks. Enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Demant A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Demant A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.